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E2F-1 but not E2F-4 can overcome p16-induced G1 
cell-cycle arrest
David J. Mann and Nic C. Jones
Background: The transition from G1 to S phase is the key regulatory step in the
mammalian cell cycle. This transition is regulated positively by G1-specific cyclin-
dependent kinases (cdks) and negatively by the product of the retinoblastoma
tumour suppressor gene, pRb. Hypophosphorylated pRb binds to and inactivates
the E2F transcription factor, which controls the expression of genes required for
S-phase progression. Hyperphosphorylation of pRb in late G1 phase results in
the accumulation of active E2F, a critical event in the progression to S phase. The
E2F factor is not a single entity, but rather represents a family of highly related
molecules, all of which bind to pRb or the pRb-related proteins p107 and p130.
Results: In this study, we have used specific inhibitors of cdks to explore the
requirements for cell-cycle progression from G1 to S phase. Expression of p16Ink4,
which specifically inhibits cyclin D-directed cdks, blocks cells in G1 phase; this
block can be overcome by expression of the viral proteins that inactivate pRb or by
E2F-1. Importantly however, the G1 arrest is not overcome by overexpression of
E2F-4. By using chimeric E2F proteins, containing amino-acid sequences from
E2F-1 and E2F-4, we have shown that their differential abilities to overcome a p16-
imposed arrest is determined by their respective amino-terminal regions. We also
demonstrate that E2F-1 can promote entry into S phase without concomitant
phosphorylation of pRb. In contrast to the p16-mediated G1 block, G1 arrest
mediated by the cdk inhibitors p21Cip1 or p27Kip1 cannot be bypassed either by
inactivation of pRb or overexpression of E2F family members.
Conclusions: These data demonstrate that the role of the cyclin D-directed cdks
in promoting the progression of cells from G1 into S phase is wholly to activate
an E2F-1-like activity through phosphorylation, thus preventing the formation of
the E2F–pRb complex. The cyclin E–cdk2 complex is also required for the G1/S
transition but has a different and as yet undefined role. We also provide evidence
for a functional difference between E2F-1 and E2F-4, dependant upon the
region that contains the DNA-binding and dimerization domains. These results
indicate that these two E2F family members are likely to regulate the expression
of different subsets of E2F-responsive promoters.
Background
The most critical step in the regulation of the cell cycle
occurs late in G1 phase, when cells must assess whether to
irrevocably commit themselves to division. Elucidation of
the molecular events governing this restriction point is
therefore of critical importance to understanding the cell
cycle. Much work has therefore centered on the G1-specific
cyclins and their catalytic partners, the cyclin-dependent
kinases (cdks), as candidate regulators of the G1 restriction
point. These include the D-type cyclins (D1, D2 and D3),
which associate with cdk4 or cdk6, and are first detected in
mid-G1 phase, and the cyclin E–cdk2 complex, which is
formed in late-G1 phase (reviewed in [1]).
Much evidence has accumulated to indicate that a critical
substrate through which the cyclin–cdk complexes control
progression through the G1 restriction point is the product
of the retinoblastoma gene, pRb (reviewed in [2]). During
most of G1, pRb is hypophosphorylated. At about the time
that the restriction point is reached, pRb becomes hyper-
phosphorylated, and this state is maintained until the cell
has undergone mitosis [2], thus completing the cell cycle.
Complexes regulated by cyclins D and E have been
shown to phosphorylate pRb in vitro [3,4] and are
therefore potential candidates for the in vivo pRb kinase.
At the molecular level, hypophosphorylated, but not hyper-
phosphorylated, pRb can bind to a number of different
proteins, including members of the E2F transcription factor
family [2,5,6]. This pRb-mediated sequestration inhibits
E2F’s activity [7–10], blocking activation of genes essential
for S-phase progression. The importance of this switch is
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emphasized by the way oncoproteins of a number of DNA
tumour viruses specifically target the hypophosphorylated
form of pRb, releasing active E2F, hence favouring the
execution of the G1/S transition (reviewed in [11]).
The E2F factor is a heterodimeric complex, consisting of
an E2F subunit and a DP subunit [12,13]. Three distinct
DP subunits have been reported to date [12,14–17]. DP-1
is the most widespread of these, and functions to regulate
binding of the associated E2F subunit to DNA [15,16].
Five E2F subunits have been characterized [6,18–24]. All
are structurally similar, consisting of a DNA-binding
domain towards the amino terminus, an adjacent dimeriza-
tion region and a carboxy-terminal transactivation domain.
Within the transactivation domain, each E2F family
member contains a discrete region which directs its associ-
ation with a pRb family member: E2F-1, E2F-2 and E2F-
3 interact with pRb in preference to p107 and p130
[6,18,19,21,25], whereas E2F-4 and E2F-5 associate with
p107 and p130 rather than pRb [22–24]. Changes in the
cellular composition of E2F complexes containing each of
these pRb-like proteins have been observed during the
G1/S transition (reviewed in [2,22]).
Additional complexities in the control of the G1/S transi-
tion became apparent following the isolation of negative
regulators of the cdks. Two families of mammalian cdk
inhibitors have been identified (reviewed in [26]). The
first family consists of p16Ink4, p15Ink4B, p18Ink4C and
p19Ink4D [27,28–31], each of which contains ankyrin repeats
and can specifically inhibit the cyclin D-directed kinases,
cdk4 and cdk6 [28–32]. The second family consists of
p21Cip1, p27Kip1 and p57Kip2 [33–40]. Members of this
family share a region of sequence homology at their amino
termini that is essential for their inhibitory activity. Using
an in vitro assay, these proteins have been shown to inhibit
multiple cyclin-dependent kinases [34,35,37,38,41]. Over-
expression of members of either inhibitor family in
mammalian cells leads to their arrest in the G1 phase of the
cell cycle [28,37,38,41,42].
Here, we use these cdk inhibitors to analyze the roles of
the cdks and the different E2F family members in the
regulation of the G1/S transition. We show that the cyclin
D–cdk complexes are primarily involved in the release of
E2F from pRb, an event which is known to induce entry
into S phase. This event can be bypassed by the expres-
sion of E2F-1 but not E2F-4. The characterization of
hybrid E2F proteins suggests that the difference between
these two E2F family members is dictated by their DNA-
binding domains. E2F-1 and E2F-4 thus seem to be able
to interact with different subsets of E2F-responsive genes.
In addition, free E2F is insufficient to drive cells into S
phase under conditions where cyclin E–cdk2 activity is
inhibited, indicating that the cyclin E–cdk2 holoenzyme
plays an alternative role in the G1/S transition.
Results
p16 arrests cells in G1 phase in a pRb-dependent manner
The strategy for our analysis uses the cdk inhibitors p16,
p21 and p27. Of these G1-specific cdks, p16 only inhibits
the catalytic subunits of the D-type cyclins, namely cdk4
and cdk6, whereas p21 and p27 inhibit cyclin D- and
cyclin E-directed cdks. We investigated which molecules
were able to overcome G1 arrests induced by these cdk
inhibitors, specifically looking for differences between a
p16-imposed blockade and a p21- or p27-induced arrest,
because such differences would highlight the roles of each
of the G1-specific cyclin–cdk holoenzymes.
The pRb-positive human osteosarcoma cell line, U2-OS,
was transiently transfected with a plasmid encoding either
wild-type p16 or a mutant p16 (with proline 114 replaced
by leucine) that no longer interacts with its target cdks
[42], together with a plasmid encoding the cell-surface
marker CD8 to allow subsequent detection of transfected
cells. Cells were harvested after 48 hours and CD8 expres-
sion was detected using a monoclonal antibody coupled to
Figure 1
Release of p16-imposed G1 arrest by DNA tumour virus oncoproteins
and E2F-1. U2-OS cells were transfected with plasmids encoding the
cell-surface marker CD8, p16, the viral oncoproteins or the E2F-1
derivatives, as indicated. Data are represented as the percentage
change in the number of cells in G1 phase of the cell cycle, relative to
the G1 population of cells transfected with the plasmid encoding CD8
only. The bars represent the average of at least three separate
experiments, each performed in duplicate. Standard errors are
displayed except where too small to depict clearly. At least 15 000
cells were gated for each sample. Untransfected cells displayed the
following cell-cycle distribution: G1, 45 %; S, 23 %; G2/M, 32 %.
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fluorescein isothiocyanate (FITC). Cells were then fixed,
cellular DNA was stained using propidium iodide and
cells were analyzed by fluorescence-activated cell sorting
(FACS). Figure 1 shows that cells transfected with the
plasmid encoding wild-type p16, but not the p16 mutant
unable to bind to cdks, accumulated in the G1 phase of
the cell cycle.
We next analyzed the effects of co-transfecting various
viral oncogenes or the E2F-1 cDNA on this p16-imposed
G1 arrest. Figure 1 shows that SV40 T antigen, adeno-
virus E1a and HPV16 E7 could completely or partially
prevent the imposition of a G1 arrest by p16. These viral
oncoproteins are known to disrupt complexes containing
pRb family members (pRb, p107 and p130) and abrogate
their restraining influence on the G1/S transition
(reviewed in [11]). A mutant form of E1a, with conserved
region 2 was deleted (E1aDCR2 [43]), which no longer
interacted with pRb family members [44], failed to
release the p16-induced arrest (Fig. 1). The plasmids
encoding E1a and E1aDCR2 have been previously shown
to direct the expression of similar amounts of protein [44].
As an additional control, U2-OS cells were transfected
with plasmids encoding E1a or E7 in the absence of p16.
Cells transfected with these oncoproteins displayed
essentially an identical cell-cycle profile to their untrans-
fected counterparts (data not shown).
To define further the roles of the different members of the
pRb family in this event, we used a variant of HPV E7, in
which the LXCXE motif (single-letter amino-acid code; X
is any amino acid), responsible for targeting complexes
containing pRb-like proteins, was mutated to LXCXG
[45]. This form of E7 cannot disrupt pRb complexes, but
can interact with p107 (and presumably p130) [45,46], and
has been previously shown to be expressed at similar
levels to wild-type E7 [46]. As shown in Figure 1, this con-
struct was totally ineffective in releasing a p16-induced
arrest, indicating that G1 arrest in these cells was linked
specifically to the presence of functional pRb, and that it is
pRb complexes (rather than those containing p107 or
p130) that are essential for restraining the G1/S transition.
Of the proteins that interact with pRb through the pocket
domain, evidence suggests the primary regulators of G1
progression are E2F family members. We therefore tested
whether E2F-1 could prevent the accumulation of cells in
G1 resulting from wild-type p16 overexpression. As shown
in Figure 1, E2F-1 was as effective as the viral oncoproteins
in this respect, completely abolishing p16-induced accumu-
lation of cells in G1 phase. This ability was dependent
upon E2F-1’s DNA-binding activity, because a mutant
form of E2F-1 with no DNA-binding activity [47] was
unable to prevent G1 arrest mediated by wild-type p16.
This non-DNA-binding mutant was still able to bind pRb
[47], so the release of p16-induced G1 arrest was not due to
the release of sequestered endogenous protein from pRb.
These results provide evidence that E2F is the critical
activity regulated by pRb, and cyclin D–cdk holoenzymes
are essential for the generation of active, ‘free’ E2F in vivo.
We next performed arrest–release experiments using the
more general cdk inhibitory proteins, p21 and p27 (Fig. 2).
Again, cells co-transfected with the plasmid encoding the
CD8 marker and plasmids encoding either p21 (Fig. 2a) or
p27 (Fig. 2b) arrested with a 2n DNA content. As with p16,
Figure 2
Differential effects of the DNA tumour virus
oncoproteins in release of (a) p21- and (b)
p27-imposed G1 arrests. U2-OS cells were
transfected with plasmids directing the
expression of CD8, p21 or p27 and the
indicated oncoprotein or E2F-1 derivative.
Data representation is as described in Fig. 1.
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this arrest could be at least partially relieved by co-transfec-
tion with the plasmid encoding T antigen. However, the
viral proteins that cause transformation primarily by disrup-
ting pRb pocket protein interactions (E1a and E7) were
ineffective in preventing G1 arrest upon co-transfection
with p21 or p27. In addition, E2F-1 was also unable to
suppress the arrests mediated by either p21 or p27.
The failure of E2F-1 to overcome a p21- or p27-imposed
arrest was not a result of a block in its activity. Changes in
E2F activity following transfection of U2-OS cells with
plasmids encoding E2F-1 or SV40 T antigen were monit-
ored using an E2F-dependent reporter (the chlorampheni-
col acetyltransferase (CAT) gene driven by the E2A
promoter, E2A-CAT). An increase in E2F activity was
detected regardless of whether the cells were co-trans-
fected with plasmids directing expression of p16, p21 or
p27 (Fig. 3, bars labelled E2F-1); as an inhibitor-negative
control, cells were transfected with the vector expressing
the non-inhibitory mutant p16. As expected, the expression
of T antigen also resulted in an elevation in E2F activity,
and again the level of activation was not influenced by any
of the inhibitors. Two conclusions follow from these results.
Firstly, the failure of transfected E2F-1 to overcome p21- or
p27-induced cell-cycle arrest was not due to any inhibition
of its activity, implying that these cdk inhibitors block
essential events unconnected with E2F-1 activation. Sec-
ondly, the enhancement of E2F activity induced by T
antigen was not the only event leading to partial release of
the p21- or p27-mediated arrest, because co-transfection of
the plasmid encoding E2F-1 led to a similar elevation in
E2F-driven transcription but failed to release the arrest.
Taken together, the results of the experiments using the
cdk inhibitors indicate that the primary function of cyclin
D–cdk4 or cyclin D–cdk6 complexes, whose activity is
specifically inhibited by p16, is to release sequestered E2F
from pRb, and that cyclin E–cdk2 is required to perform
some other function in the transition from G1 to S phase.
Unlike p27, the p21 protein is also able to bind to proliferat-
ing cell nuclear antigen (PCNA) [48], and thereby prevent
DNA replication [49,50]. Because we observed identical
effects when p21 or p27 were expressed, these results must
be independent of the interaction between p21 and PCNA.
E2F family members have different abilities to release a
p16-induced G1 arrest
The results with DNA tumour virus oncoproteins (Fig. 1)
indicated that complexes containing pRb, rather than those
containing p107 (or p130), were important in regulation of
the G1/S transition. One interpretation of these results was
that E2F family members specifically regulated by p107 or
p130, in contrast to those regulated by pRb, might be
unable to promote progression into S phase in the presence
of p16. We addressed this possibility by testing the ability
of E2F-4, which is reg ulated in vivo by p107, to release a
Figure 3
Elevated E2F-1 activity alone is insufficient to
release a p21- or p27-imposed G1 arrest. U2-
OS cells were transfected with plasmids
encoding the E2A–CAT reporter, an inhibitor
protein and either E2F-1 or SV40 T antigen.
All transfections included a plasmid directing
the expression of b-galactosidase. Cells were
harvested and assayed for CAT activity, which
was normalized for variable transfection
efficiencies by correcting for b-galactosidase
activity.
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p16-induced G1 arrest. Figure 4 clearly demonstrates that
overexpression of E2F-4 was unable to prevent the p16-
imposed G1 arrest. The inability of E2F-4 to release the G1
arrest was unlikely to result from its inactivation by endoge-
nous p107, because it was able to transactivate an E2A-
CAT reporter plasmid as efficiently as E2F-1 (see below).
To investigate the molecular basis for the differential abili-
ties of E2F-1 and E2F-4 to release a p16-imposed G1
arrest, we constructed chimeric E2F molecules. Using a
PCR-based approach, we introduced into the cDNA
encoding E2F-4 a BglII site in the equivalent position to
the unique BglII site in the E2F-1 cDNA immediately
following the DNA-binding and dimerization domains.
Two chimeric E2F proteins were then generated (Fig. 5a):
in the first (E2F-1/4), the amino terminus of E2F-1, which
contains the DNA-binding and dimerization domains, was
fused to the carboxyl terminus of E2F-4, which contains
the transactivation domain; in the converse construct (E2F-
4/1), the amino terminus of E2F-4 was fused to the transac-
tivation domain of E2F-1. These chimeric E2F molecules,
like E2F-1, were epitope tagged at their amino termini
with the hemagglutinin epitope and this property was used
to analyze the levels of protein expression by these const-
ructs. Western immunoblot analysis of transfected cells
clearly indicated that equivalent levels of wild-type E2F-1
and other fusion proteins were synthesized (Fig. 5b).
After analysis of expression levels, we tested the ability of
these fusion proteins to activate the E2A–CAT reporter
(Fig. 5c). Both E2F-1 and E2F-4 were equally effective at
activating this reporter. However, as shown previously
[22,23], they differed in their sensitivity to repression by
pRb and p107; E2F-1 was most sensitive to pRb inhibi-
tion, whereas E2F-4 was repressed by p107. Both fusion
proteins were able to transactivate the reporter. Further-
more, as expected, the fusion proteins were inhibited by
pRb or p107, depending on the nature of their transactiva-
tion domains (Fig. 5c). Thus, E2F-1/4 was repressed by
p107 but not by pRb, whereas E2F-4/1 was inhibited by
pRb but not by p107. This clearly demonstrates that, in
transfected U2-OS cells, each of the E2F constructs
directed the expression of equivalent amounts of active
E2F protein. Both of these fusion proteins were then used
in the p16 arrest–release assay. Figure 5d shows that E2F-
1/4 was effective in preventing the p16-induced arrest,
whereas E2F-4/1 was not. Thus, the release from arrest
was dependent upon the presence of the amino terminus
of E2F-1.
pRb phosphorylation status in arrested and released
cells
We addressed the question of the phosphorylation status
of pRb in arrested and released cells. U2-OS cells were
transfected with plasmids encoding CD8, wild-type p16
and either wild-type E2F-1 or the non-DNA binding
mutant. Cells were harvested and transfected cells were
tagged with FITC via antibodies against the CD8 surface
marker. FITC-labelled cells were then physically sepa-
rated from the bulk untransfected population of cells by
FACS, and only cells with a greater than 100-fold
enhancement of fluorescence, compared to untransfected
cells, were retained in the CD8-positive population.
Western blots were performed on the sorted cells to
analyze the pRb banding pattern, which is indicative of its
phosphorylation status. As shown in Figure 6, cells co-
transfected with plasmids expressing wild-type p16 and
mutant E2F-1 arrested in G1 phase and contained pRb
which migrated primarily as a single band of 105 kDa,
characteristic of the hypophosphorylated protein. This is
in contrast to the untransfected cells, in which pRb
migrated largely as a mixture of high molecular weight
species, diagnostic of the hyperphosphorylated protein.
Cells co-transfected with plasmids expressing p16 and
wild-type E2F-1 displayed a cell-cycle profile indistin-
guishable from that of untransfected cells. However,
examination of the pRb in these cells demonstrated that it
was predominantly in the hypophosphorylated form.
Therefore, cells released from the p16 arrest by expression
of E2F-1 can traverse the G1/S boundary by bypassing the
requirement for concomitant phosphorylation of pRb.
Discussion
The results described above are consistent with the
transition from G1 to S phase of the cell cycle being
achieved by the execution of two distinct events. One of
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Figure 4
E2F-4 cannot release a p16-imposed G1 arrest. U2-OS cells were
transfected with plasmids directing the expression of CD8, p16 and
either E2F-1 or E2F-4. Data representation is as described in Fig. 1.
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these is governed by the cyclin D-directed kinases and is
primarily involved in the generation of ‘free’ E2F-1-like
activity. This is achieved when the cyclin D–cdk holoen-
zymes phosphorylate pRb [3,4], and possibly also E2F-1
(D.J.M . and N.C.J., unpublished observations), thereby
precluding the formation of inhibitory pRb–E2F
complexes. The ‘free’ E2F-1-like activity is then able to
transactivate its target genes, hence facilitating entry into
S phase. The ‘free’ E2F generated must display the
DNA-binding specificity of E2F-1, as overexpression of
E2F-4 was not effective in releasing a p16-induced arrest.
The release of the p16 arrest by E2F-1 is unlikely to be
because E2F-1 up-regulates cyclin D or cdk4 expression,
because elevated E2F-1 levels have been shown to have
no effect on the expression of these kinase components
[51]. In addition, the demonstration that pRb remains
hypophosphorylated in cells released from a p16-mediated
arrest by E2F-1 also argues against the presence of active
cyclin D–cdk complexes in these cells. 
Although elevated E2F-1 activity alone is sufficient to
release a p16-imposed G1 arrest, it is insufficient to release
the G1 arrest in cells overexpressing p21 or p27. This
implies one of two possibilities. The first possibility (Fig.
7a) is that cyclin E–cdk2 activation may occur downstream
of E2F-1, but the endogenous mechanism by which cyclin
E–cdk2 is activated is not sufficiently powerful to over-
come the exogenous p21- or p27-induced arrest. However,
we found that the E2F activity obtained when plasmids
expressing p21 (or p27) and E2F-1 were co-expressed (and
the cells were arrested) was similar to that found in cells
co-transfected with plasmids encoding p21 (or p27) and
SV40 T antigen (these cells were partially released from
arrest). This would suggest that ‘free’ E2F is not directly
activating cyclin E–cdk2 complexes, or if it is, it is not suf-
ficient to overcome the p21- (or p27-) mediated inhibition.
The second possibility consistent with our data (Fig. 7b)
is that cyclin E–cdk2 lies on an alternative pathway to
E2F-1; both of these pathways would then need to be trig-
gered to execute the G1/S transition. This model would be
consistent with that proposed by Restnitzky and Reed
[52], based on the analysis of the timing of S-phase entry in
cells expressing cyclin D1 and/or cyclin E from inducible
promoters. Expression of either cyclin alone caused a small
reduction in the time required to proceed from G0 into S
phase, indicating that both cyclins D1 and E are rate limit-
ing for this transition. However, expression of both cyclins
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Figure 5
The release of the p16-imposed arrest is due
to the presence of the E2F-1 DNA-binding
domain. (a) Schematic representation of the
parental and chimeric E2F proteins. (b) U2-OS
cells were transfected with plasmids directing
the expression of CD8 and either wild-type
E2F-1, E2F-1/4 or E2F-4/1. Cells were
harvested 48 h after transfection and CD8 was
tagged with a FITC-conjugated anti-CD8
antibody. CD8-positive and CD8-negative cells
were then physically separated by FACS.
Equal numbers of cells were lysed in SDS–
PAGE loading buffer, separated on 10 %
polyacrylamide gels and subjected to western
immunoblot analysis using the anti-
hemagglutinin antibody. Protein from
approximately 1 × 105 cells was loaded in each
lane. The arrowhead marks the position of the
hemagglutinin-tagged E2F protein. (c) Analysis
of the properties of the parental and chimeric
E2F constructs. U2-OS cells were transfected
with a plasmid containing the E2A-CAT
reporter, the indicated E2F construct and
empty vector or vector directing the expression
of either pRb or p107. Cells were harvested
and assayed for CAT activity, which was
normalized for variation in transfection
efficiency as described in Fig. 3. (d) The E2F-
1/4 fusion protein can release the p16-
imposed G1 arrest, but the E2F-4/1 construct
cannot. U2-OS cells were transfected with
plasmids directing the expression of CD8, p16
and the E2F fusion protein. Data representation
is as described in Fig. 1.
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together caused a synergistic reduction in the duration of
the G0 to S transition, demonstrating that the two cyclins
function on separate pathways [52]. Our data are entirely
consistent with this model, and further demonstrate that
the crucial factor activated by the cyclin D-dependent
branch of this scheme is an E2F-1-like activity.
Results from other experimental systems have recently
emerged supporting the view that the pathway involving
pRb, E2F, cyclin D, cdk4/6 and p16 is involved in
controlling the G1/S transition. Microinjection of antibodies
against cyclin D1 arrests pRb-positive cells in G1 phase
[53,54]. However, when the same experiments are perfor-
med in cell lines where pRb function is either abrogated by
mutation or compromized by expression of a neutralizing
oncogene, such as SV40 T antigen, cells cycle normally,
indicating that cyclin D–cdk complexes are not essential for
G1 progression in these cells [53,54]. Cells that do not
produce functional pRb are also insensitive to arrest by p16
[42]. Mutation of pRb renders it unnecessary to disrupt
pRb–E2F complexes by cyclin D-directed phosphorylation.
Similar experiments have been performed recently with
antibodies against cyclin E. In this case, all cells tested
arrested in G1, irrespective of their pRb status [55]. Such
data indicate that cyclin D–cdk, but not cyclin E–cdk2,
acts upstream of pRb. The critical targets regulated by
cyclin E–cdk2 are as yet unknown. They must, however,
be independent of proteins that bind to the pocket domain
of pRb, because adenovirus E1a and HPV E7, which
disrupt pRb complexes, were unable to release a p21- or
p27-mediated G1 arrest (Fig. 2), and cells released from a
p16-induced arrest by co-expression of E2F-1 are able to
cycle with pRb in the hypophosphoryla ted state (Fig. 6).
Recently, DeGregori et al. [56] have also demonstrated
that overexpression of E2F-1 can prevent a p16-mediated
cell-cycle arrest. However, in contrast to our data, these
Figure 7
Model representing potential routes through
the G1/S transition (see text for details).
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Figure 6
Dissociation of the requirement for pRb
hyperphosphorylation and progression
through the G1/S transition. U2-OS cells
were transfected with plasmids directing the
expression of CD8, p16 and either wild-type
or non-DNA-binding mutant E2F-1. 48 h after
transfection, cells were harvested and
expressed CD8 protein tagged with a FITC-
conjugated anti-CD8 antibody. CD8-positive
and CD8-negative cells were then physically
separated by FACS. Cells were then lysed in
SDS–PAGE loading buffer, separated on
7.5 % polyacrylamide gels and subjected to
western immunoblot analysis. Protein from
approximately 1 × 105 cells was loaded in the
CD8-positive lanes, and 2.5 × 105 cells in the
CD8-negative lanes. The migration positions
of hypophosphorylated and hyperphos-
phorylated pRb are indicated.
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authors suggest that such overexpression can also release a
p21- or p27-mediated arrest. The reasons for this discrep-
ancy are unclear at present.
Because of its central role in the restraint of entry into  S
phase, the identification of the physiological pRb kinase
has received considerable attention. Our demonstration
that cells co-expressing p16 and E2F-1 cycle with pRb in
the hypophosphorylated state indicates that cdk4 and
cdk6, the catalytic partners of the D-type cyclins, play a
central role in pRb phosphorylation. Previous studies in
which cyclin D1 or cyclin E are ectopically expressed from
an inducible promoter have demonstrated that phosphory-
lation of pRb correlates with the induction of cyclin D1,
rather than cyclin E [52]. The pRb protein has also been
shown to be the preferred substrate for cyclin D-directed
cdks in vitro, although in vitro hyperphosphorylation of
pRb can also be achieved by cyclin E–cdk2 as well as
cyclin A–cdk2 (reviewed in [2]).
Our data also demonstrate that the critical factor regulated
by pRb is an E2F-1-like activity. Overexpression of E2F-1
alone is able to bypass the requirement for hyperphos-
phorylation of pRb and induce entry into S phase. It could
be argued that, by overexpressing E2F-1, other pocket-
bound proteins are competed from pRb by the excess
E2F-1, and it is these proteins that are then able to trigger
the G1/S transition. This possibility can be excluded,
however, because overexpression of the non-DNA-
binding E2F-1 mutant was completely unable to release
the p16-imposed arrest. This mutant is unchanged in its
ability to interact with pRb [47]. Thus, in U2-OS cells,
E2F-1-like family members are the essential pRb-
regulated factors required for the G1/S transition. Other
pRb-binding proteins, such as c-abl, c-Myc and ATF-2,
may play a supportive role during the progression into S
phase, but their activities are not sufficient for this
process.
Our results also highlight functional differences between
the E2F family members, in that E2F-1, but not E2F-4,
was able to prevent a p16-imposed G1 arrest. This differ-
ence is unlikely to be a result of the relative strengths of
the transactivation domains of these two transcription
factors. When the E2F-4 transactivation domain was fused
to the E2F-1 DNA-binding/dimerization region, it was
slightly more potent in its ability to activate an E2A-CAT
reporter than wild-type E2F-1 (Fig. 5c). Also, Hijmans et
al. [24] have demonstrated that the transactivation
domains of these two E2F family members are equally
effective in reporter assays when fused to a heterologous
DNA-binding domain.
Our experiments with chimeric E2F proteins indicated
that the amino-terminus of E2F-1 was essential to
prevent a p16-induced arrest. This region contains the
DNA-binding and dimerization domains, as well as a site
that is involved in interacting with cyclin A [57,58].
Although our results do not directly distinguish between
the importance of these different domains, it is likely that
the effect is due to the DNA-binding portion of the mole-
cule alone. The dimerization domain is unlikely to be
involved, because both E2F-1 and E2F-4 seem to display
no specificity in the selection of their heterodimerization
partners [12]. Similarly, the cyclin A-interaction site is
unlikely to be the basis for the different activities,
because this interaction is important for down-regulating
E2F-1 activity during the S/G2 phase of the cell cycle,
rather than the G1/S transition [57,58]. Thus, the differ-
ence between E2F-1 and E2F-4 seems to be attributable
to their relative DNA-binding specificities. The DNA-
binding domains do, however, display significant struc-
tural homology and indeed, one means by which E2F-4
was isolated involved a strategy based on the sequence
conservation in the DNA-binding region of the E2F
family members [22,23].
Some differences in the DNA-binding specificity of E2F-
1 and E2F-4 have been indicated previously. In compari-
son to E2F-1, E2F-4 was inefficient in transactivating a
synthetic promoter containing four E2F-binding sites
driving a CAT reporter [16,22]. In vivo, E2F-binding sites
in certain promoters seem to be regulated by either pRb or
p107, indicating the involvement of different E2F family
members (reviewed in [2]). Here, we have demonstrated a
functional difference between the DNA-binding domains
of E2F-1 and E2F-4 in vivo. Thus, it seems likely that
E2F-1 and E2F-4 will transactivate different subsets of
responsive genes.
The finding that E2F-1 but not E2F-4 could release the
p16-induced G1 arrest also substantiates the observation
that dysregulation of components of the pRb pathway can
lead to uncontrolled proliferation. Thus, many genetic
changes in the components of the pRb pathway (pRb
itself, cyclin D1, p16 and cdk4) have been associated with
cancerous outgrowth [2,59,60]. No predisposing mutations
in components of the p107 or the p130 pathways have
been described to date, despite extensive investigation,
indicating the pre-eminence of the pRb pathway in the
regulation of the G1/S transition.
SV40 T antigen could release both p16- and p21/p27-
imposed arrests (Figs 1,2),  and release from both types of
arrest was accompanied by elevations in the endogenous
E2F activity (Fig. 5). On its own, however, this elevation
in E2F activity was not sufficient to release the p21- or
p27-induced G1 arrests. This result indicates that SV40 T
antigen must possess some additional property which
enables it to overcome the effects of p21 and p27. We are
currently investigating this T-antigen specific function
using mutant forms of the protein.
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Conclusions
In summary, we have provided evidence that the transition
from G1 into S phase is controlled by two parallel path-
ways: one involves cyclin E–cdk2, and is independent of
pRb and E2F; the other requires the phosphorylation of
pRb by cyclin D–cdk complexes in order to generate ‘free’,
active E2F. The cellular requirement for pRb phosphory-
lation normally associated with the G1/S transition can be
abolished if E2F-1 is overexpressed, indicating that E2F is
the major factor regulated by pRb. Also, the observation
that E2F-1, but not E2F-4, can release a p16-imposed G1
arrest, and that this ability is most probably conferred by
the DNA-binding domain of E2F-1, indicates that these
two E2F family members may transactivate different sets
of genes.
Materials and methods
Plasmid constructs
The plasmids used to express the following proteins have been
described elsewhere: SV40 T antigen [61], adenovirus E1a and
E1aDCR2 [43], HPV16 E7 and the E7 LXCXG mutant [45,46], E2F-1
[62] and E2F-4 [22]. The cDNAs encoding p16, p21 and p27 were gifts
from G. Peters; each was cloned into the mammalian expression vector
pJ7V [63].
To construct E2F-1/4, PCR was performed using E2F-4 cDNA [22] as
template and the oligonucleotides 5′–GCGCAGATCTGCACACTCTTC-
AGGTGAATCTGG–3′ and 5′–GCGCGGATCCACCATGGCGGAGG-
CCGGGCCACAGG–3′. The resulting fragment was digested with
BamHI and BglII and ligated into plasmid pcDNAI-HA-E2F-1 [62] cut
with the same enzymes. To construct E2F-4/1, PCR was performed
using E2F-4 cDNA as template and oligonucleotides 5′–GCGCA-
GATCTCCATTGAGGTTCTGCTGGTGAACAAGG–3′ and 5′–GCGC-
GAATTCAGAGGTTGAGAACAGGCAC–3′. The resulting fragment was
digested with EcoRI and BglII and ligated into pcDNAI-HA-E2F-1 [62]
cut with the same enzymes.
Cell culture, transfection and FACS analysis
U2-OS cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10 % fetal calf serum. Cells were transfected as
described [64]. Each transfection experiment was performed at least
three times with different batches of DNA. Cells, plated in 9 cm dishes,
were transfected with the following amount of plasmid per dish: CD8,
0.5 µg; p16, p21 or p27, 2.5 µg; other effector plasmids, 10 µg. Cells
transfected for reporter assays were processed as described [65], and
transfection efficiency was monitored by including 2 mg pJATLAC in each
transfection and assaying extracts for b-galactosidase activity [66].
For FACS analysis, cells were harvested 48 h after transfection by incu-
bation with 0.5 % trypsin, 0.02 % EDTA in phosphate buffered saline,
and were subsequently collected by centrifugation at 1000 rpm for 3 min
at 4 oC. Cells were washed once with solution I (3 % bovine serum
albumin, 0.02 % sodium azide in phosphate buffered saline) and resus-
pended in 300 ml solution I containing 0.2 mg FITC-conjugated anti-CD8
antibody (DAKO A/S, Denmark). Antibody binding was allowed to
proceed for 45 min on ice, after which cells were washed 3 times with
5 ml solution I. Following the final wash, cells were resuspended in
300 ml 0.02 % sodium azide in phosphate buffered saline and then
700 ml absolute ethanol was added to fix the cells. Cells were then
stained with propidium iodide and FACS analysis was performed using a
Becton Dickinson FACS Vantage.
Western immunoblotting
Western analysis was performed as described by Harlow and Lane [67]
using the G3-245 anti-human pRb antibody (Pharmingen, San Diego,
USA). or the 12CA5 anti-hemagglutinin antibody (Boehringer Mannheim,
Germany). The signal was detected using anti-mouse IgG-horse radish
peroxidase-conjugated antibody and Enhanced Chemiluminescence
(Amersham, UK).
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